60 likes | 148 Views
Intellectual Property-related challenges: A Latin America Perspective GraciaVioleta Ross graciavioleta@gmail.com Wednesday 25 th , July 2012 Medicines Patent Pool Mini-Satellite Washington, DC. Latin America …. 75% coverage for ART?. OR Invisible realities ?.
E N D
Intellectual Property-related challenges: A Latin America Perspective GraciaVioleta Ross graciavioleta@gmail.com Wednesday 25th, July 2012 Medicines Patent Pool Mini-Satellite Washington, DC
LatinAmerica… 75% coveragefor ART? OR Invisible realities?
ConcernsforLatinAmerica • One of the most inequitable regions in wealth distribution, access to health and poverty levels. • In many countries in Latin America, treatment failure is resulting in increased need for second line medicines and even third line treatment. • There is a shocking amount or antiretrovirals ALREADY PATENTED in the region, also in Bolivia (a tinny market for the big pharmaceutical industry, we have 1980 PLHA on ART), but even in this case the tendency in the patentability of ARV is sadly evident. • Patents are worst in bigger countries considered to be potential markets for the industry (e.g. Argentina, Chile, Brazil). The macro-economic levels might be on the rise, but this does not mean PLHA in the grassroots have resources to buy their medications.
ConcernsforLatinAmerica • Most Central America countries signed free trade agreements with the US, as a result, there are stronger patent protection and data exclusivity as well. • Patents in India WILL ALSO BLOCK ACCESS to ARV in Latin American countries that have GF support. • Latin America also has to deal with the labeling of “middle income countries”, this name, virtually ELIMINATES Latin America from the global policy making and prioritizing of international aid.
The Medicines Patent Pool… • Itisone (amongothers) mechanismsthat can help in theachievment of thegoal of UNIVERSAL ACCESS. • Becauseitisbasedonvoluntarylicenceswithpharmaceuticalcompanies, itislimited, butrightnowistheonlymechanismavailable, (notledbythecompanies), thatspecificallyadressestheissues of licenses. • Somecompanieshavetheirownlicensingpolicies, yes, butthosewillnotincludeLatinAmerica (ifany, thosewillbefocused in Africa)
Thetreatmentadvocates • Thecurrent global tendencieson ARV, patents and reduction of HIV funding (includingforARVs), MUST be a SERIOUS CONCERN forall PLHIV living in developingcountries, alsoforLatinAmerica. • Latin American civil societyisone of thestrongest in thedevelopingworld. (Are westill?) • Itis time toendthevacation of the AIDS treatmentadvocates. Itis time towake up, otherwise, wewillbeleftto die. • I wishLatinAmericacouldbeknownforitszerolaziness in terms of treatmentadvocacyfor HIV, whichincludesadvocacyrelatedtopatentsfor ARV.